Clinical Impact of Interferon-γ in Anti-Citrullinated Protein Antibody-Positive Rheumatoid Arthritis

Kijun Lee
Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

Hong Ki Min
Division of Rheumatology, Department of Internal Medicine

Seong-Hee Ko
Department of Food and Nutrition, College of Human Ecology, Sookmyung Women’s University, Seoul 04310, Republic of Korea

Sang-Heon Lee
Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05030, Republic of Korea

Hae-Rim Kim
Division of Rheumatology, Department of Internal Medicine, Research Institute of Medical Science, Konkuk University School of Medicine, Seoul 05030, Republic of Korea

Ji Hyeon Ju
Catholic iPSC Research Center, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea. Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

Ho-Youn Kim (✉ ho0919@gmail.com)
Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

Research

Keywords: early rheumatoid arthritis, helper T cell, microarray, interferon-γ, remission

DOI: https://doi.org/10.21203/rs.3.rs-52935/v1

License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background: CD4⁺ T cells are crucial for the pathogenesis of rheumatoid arthritis (RA). The roles of gene overexpression in CD4⁺ T cells and the predictive roles of Th1- and Th17-related cytokines have not been clearly defined in patients with RA. Here, we investigated gene expression levels in CD4⁺ T cells in methotrexate (MTX)-naïve early RA (eRA) and evaluated changes in CD4⁺ T-cell-related cytokines during eRA.

Methods: Patients with anti-citrullinated protein antibody (ACPA)-positive MTX-naïve eRA were recruited. Patients with osteoarthritis were evaluated as controls. Microarray analysis was used to identify overexpressed genes in CD4⁺ T cells, and reverse transcription quantitative polymerase chain reaction was used to validate the identified genes. Plasma cytokine levels were measured, and correlations with disease activity were assessed.

Results: Thirty-four genes showed overexpression in CD4⁺ T cells from patients with ACPA-positive MTX-naïve eRA compared with controls. Nineteen were related to interferon (IFN)-γ, and nine were related to interleukin (IL)-17A; five were related to both IFN-γ and IL-17A. Plasma levels of five cytokines were elevated in the ACPA-positive MTX-naïve eRA group compared with those in the control group, and C-X-C motif chemokine ligand 10 was significantly elevated in the ACPA-positive MTX-naïve eRA group compared with that in the established active RA and OA groups. In established RA with low disease activity, the drug-free remission group/drug reduction group showed significantly lower IFN-γ and IL-17A levels than the drug maintenance group and relapse after drug reduction group.

Conclusion: Our T2 research of IFN-γ emphasized that, not only the Th17 immune response, but the Th1 immune response is also very important for the RA pathogenesis. Concurrent increase in IFN-γ and IL-17 were observed in active stage of ACPA-positive MTX-naïve eRA, and the plasma levels of them could be useful for new clinical biomarkers before and/or after treatment of RA.

Background

Rheumatoid arthritis (RA) is a destructive systemic arthritis with an autoimmune pathogenesis. RA can destroy normal joints and induce irreversible changes in articular structures, eventually causing disability and inability to work. Reducing arthritis and preventing additional structural damage in joints are the most important goals in RA treatment, and various agents have been develop to achieve these goals [1].

Synovitis and pannus formation are the cornerstone pathologic components of RA pathogenesis. Inflamed synovium from patients with RA shows increased fibroblast-like synoviocyte (FLS) and immune cell numbers [2]. Moreover, T-cell responses to type II collagen are enhanced, particularly in early RA (eRA) [3]. These immune responses can be explained by post-translational modifications (PTM) [4], which modify the architecture of peptides to generate autoantigens. The most well-known PTM in RA is citrullination, and autoantibodies against citrullinated peptide (ACPAs) are crucial in the diagnosis and
pathogenesis of RA [5]. These modified antigens activate B cells to produce autoantibodies and stimulate antigen-presenting cells (APCs), FLSs, and T cells.

Helper T cells (cluster of differentiation [CD] 4+ T cells) are important elements in adaptive immune systems and can be divided into several subtypes [6]. In inflamed RA synovium, CD4+ T cells are predominant [7], suggesting that CD4+ T cells may be cornerstone immune cells in RA pathogenesis. Type 17 helper T cells (Th17 cells) have been identified in RA [8, 9], and before identifying Th17 cells, interferon (IFN)-γ-secreting Th1 cells have been thought as major pathologic cells in RA development [10]. IFN-γ is the main cytokine produced by Th1 cells [6], and autoreactive Th1 cells are increased in the peripheral blood and synovial fluid of patients with RA [11, 12]. However, the effects of IFN-γ in animal models are unclear [13–15]. Furthermore, trials of IFN-γ and IFN-γ-blocking therapies have shown conflicting therapeutic potentials in patients with RA [16, 17]. Thus, IFN-γ may have various effects in RA, and further studies are required.

Recent genetic and epigenetic studies have revealed genes associated with the pathogenesis of RA [18]. For example, human leukocyte antigen (HLA)-DRB1 was the first genetic risk factor shown to be associated with RA development [19], and such genetic predisposition facilitates autoimmunity of PTM autoantigens [20]. Based on a genome-wide association study, approximately 100 genetic susceptibility single nucleotide polymorphisms (SNPs) for RA were found [21]. However, most of these SNPs were not resided in protein-coding regions, and further studies of the functions and effects of the identified genes are required. Relevantly, signal transducer and activator of transcription 3 (STAT3)-inducible genes are overexpressed in CD4+ T cells from patients with undifferentiated arthritis who eventually developed seronegative RA [22]. Expression quantitative trait loci (eQTLs) are useful tools for identifying SNPs affecting disease-specific gene expression. Notably, RA-related eQTLs have been shown to be enriched in CD4+ T cells [23, 24]. Moreover, the IFN gene signature has shown to be increased in the whole blood of patients with methotrexate (MTX)-naïve RA compared with that in patients with established RA, and these changes were correlated with RA disease activity in MTX-naïve RA [25]. However, gene expression levels in CD4+ T cells in patients with MTX-naïve seropositive RA have not been clarified.

Accordingly, in this study, we investigated gene expression levels in CD4+ T cells in ACPA-positive MTX-naïve eRA and evaluated changes in CD4+ T-cell-related cytokines during eRA. The goal of this study is present to translate research from animal models (T1 research) to real patients and to identify novel biomarkers for future T2 research.

**Methods**

**Patients**

Patients were recruited from Konkuk University Hospital and Ho-Youn Kim’s Clinic for Arthritis and Rheumatism. Inclusion criteria for MTX-naïve, eRA were as follows: (1) fulfilled the 1987 American College of Rheumatology (ACR) revised classification criteria for RA or 2010 ACR/European League
Against Rheumatism classification criteria for RA [26, 27]; (2) ACPA positive; (3) over 18 years old; (4) never taken disease-modifying antirheumatic drugs (DMARDs) prior to enrolment; (5) symptom duration of arthralgia less than 1 year; and (6) presence of synovitis confirmed by ultrasonography or magnetic resonance imaging. Exclusion criteria were as follows: (1) presence of another autoimmune disease; (2) presence of infection; and (3) presence of malignancy. Patients with established RA were also recruited and were all positive for either ACPA or rheumatoid factor. Patients with established RA were divided into low disease activity or moderate to high disease activity; patients who achieved a disease activity score (DAS) 28-erythrocyte sedimentation rate (ESR) less than 3.2 were defined as having low disease activity, whereas those with DAS28-ESR of greater than 3.2 were defined as having moderate to high disease activity. Patients with osteoarthritis (OA) were recruited as a control group. Synovial fluid was obtained from patients with RA or OA when performing arthrocentesis for therapeutic purposes. In patients with ACPA-positive, MTX-naïve eRA, cytokine levels were analysed before DMARDs were started. In patients with established RA with low disease activity, cytokines were measured at the time when DAS28-ESR less than 3.2 was achieved. The disease course in patients with established RA with low disease activity was followed for 6 months, and patients were divided into the drug-free remission group, drug reduction group, drug maintenance group, and relapse after drug reduction group. Detailed information for each group is summarized in Supplementary Table 1. Informed consent was obtained from all patients, and the study was approved by the Human Research Ethics Committee of the Konkuk University Medical Center (approval no. KUH1010511) and the Clinics for Arthritis and Rheumatism (approval no. 0301202005BR00101).

**Enzyme-linked immunosorbent assay (ELISA)**

We measured C-X-C motif chemokine ligand 10 (CXCL10) protein concentrations in plasma samples isolated from the whole blood of patients by ELISA (Abcam, Cambridge, MA, USA), according to the manufacturer's instructions. Absorbance at 450 nm was read on a VersaMax microplate reader with SoftMax Pro software (Molecular Devices, Sunnyvale, CA, USA).

**Cytokine measurement via multiplex cytokine assay (MCA)**

Millipore's MILLIPLEX MAP High Sensitivity Human Cytokine multiplex kit (cat. no. HSTCMAG-28SK; Merck, Billerica, MA, USA) was used to measure plasma concentrations of IFN-γ, interleukin (IL)-17A, IL-6, IL-12, and tumour necrosis factor (TNF)-α, according to the manufacturer's instructions.

**RNA preparation**

Total RNA was extracted using TRIzol (Invitrogen Life Technologies, Carlsbad, CA, USA) and purified using RNeasy columns (Qiagen, Valencia, CA, USA). RNA samples were then quantified, aliquoted, and stored at -80 °C until use. For quality control, RNA purity and integrity were evaluated by denaturing gel electrophoresis and analysis of the optical density at 260/280 using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).
Reverse transcription quantitative polymerase chain reaction (RT-qPCR)

Total RNA (500 ng), extracted as described above, was reverse transcribed into cDNA with a RevertAid First Strand cDNA synthesis kit (Thermo Scientific, Waltham, MA, USA) according to the manufacturer's instructions. RT-qPCR was conducted in a 20-µL total volume containing 7.2 µL PCR-grade distilled water, 0.4 µL forward primers and reverse primers, and 10 µL SYBR Green I Master mix (Roche Diagnostics, Mannheim, Germany). PCR conditions were as follows: 95 °C for 10 min; followed by 35 cycles of 95 °C for 10 s, 55 °C for 10 s, and 72 °C for 10 s. All primers were synthesised by Bioneer Corp. (Daejeon, Republic of South Korea). The relative mRNA expression levels were normalised to the levels of β-actin mRNA.

Isolation of peripheral blood mononuclear cells (PBMCs) and CD4⁺ T cells

Whole blood was collected using standard blood draw procedures. PBMCs were isolated from whole blood using Ficoll-Paque density medium (GE Healthcare, Chicago, IL, USA). The heparinised blood was diluted 1:1 in phosphate-buffered saline (PBS) and layered over the density gradient. The tube was centrifuged for 30 min at 1,800 rpm at room temperature. The whitish cell layer was collected and washed in PBS. To purify CD4⁺ T cells from PBMCs, the cells were incubated with anti-human CD4 microbeads (Miltenyi Biotec, Auburn, CA, USA). CD4⁺ T cells were then separated magnetically using a MACS column.

Gene expression profiling and data analysis

Gene expression analyses were performed in CD4⁺ T cells isolated from PBMCs using Affymetrix GeneChip Human Gene 2.0 ST oligonucleotide arrays. RNA (300 ng) was applied to the Affymetrix GeneChip as recommended by the manufacturer (http://www.affymetrix.com). The Affymetrix GeneChip Human Gene 2.0 ST oligonucleotide array was then scanned using an Affymetrix Model 3000 G7 scanner, and image data were extracted and analysed using Affymetrix Command Console software 1.1. For normalisation, we used the robust multi-average algorithm implemented in Affymetrix Expression Console software.

Statistical analysis

All data were expressed as means ± standard deviations or medians with interquartile ranges. Continuous variables were compared using Student’s t tests or one-way analysis of variance and Bonferroni’s multiple comparisons test. Correlation analysis was performed using Pearson’s correlation coefficients. In all analyses, differences with P values of less than 0.05 were considered significant, and analyses were performed using SPSS version.20.0 (SPSS, Chicago, IL, USA).

Results
Upregulated genes in ACPA-positive, MTX-naïve eRA

We performed microarray analysis of peripheral blood CD4+ T cells from ACPA-positive, MTX-naïve eRA (14 patients) and OA (9 patients); expression data for 103 genes were obtained. A heatmap of total gene expression is shown in Fig. 1A. In total, 101 genes were upregulated by more than 3-fold in ACPA-positive, MTX-naïve eRA compared with those in OA; two genes were downregulated (Fig. 1B). We further selected genes that were overexpressed by at least 6-fold (34 genes; Table 1). Among the 34 genes, we clustered gene sets according to associations with IFN-γ or IL-17A. Nineteen genes were related to IFN-γ signalling, and eight were related to IL-17A signalling (Tables 2 and 3). Interestingly, five genes (IFIT3, RSAD2, GBP1, CCL20, and OASL) were related to both IFN-γ and IL-17A.

Validation of the overexpressed genes in ACPA-positive, MTX-naïve eRA and measurement of CXCL10 in peripheral blood

Ten genes (CXCL10, IFIT3, IFIT1, RSAD2, TNFAIP6, SLAMF7, IFI44, IFIH1, OASL, HERC5) were selected for validation by RT-qPCR. Except SLAMF7 and IFI44, all genes showed overexpression in ACPA-positive, MTX-naïve eRA (n = 5) compared with that in OA (n = 5; Fig. 1C). Next, we measured protein levels of the most prominently overexpressed gene, CXCL10, in plasma samples from patients with ACPA-positive, MTX-naïve eRA, established RA, or OA. CXCL10 levels were significantly higher in ACPA-positive, MTX-naïve eRA than in established RA or OA (Fig. 1D). However, plasma CXCL10 levels did not correlate with clinical disease activity, DAS28-ESR, or other laboratory parameters (data not shown).

Comparison of IFN-γ levels between MCAs and sandwich ELISA in ACPA-positive, MTX-naïve eRA

To compare the sensitivity of ELISA and MCA, IFN-γ levels in the plasma of the same ACPA-positive, MTX-naïve eRA patient (N = 20) were measured. Mean plasma IFN-γ levels were higher in MCA than ELISA (39.2 ± 19.6 vs 7.5 ± 4.6 pg/ml, P < 0.0001). The detectable level of IFN-γ was wider in MCA than in ELISA (0.61–2500 vs 15.6–1000 pg/ml, respectively).

Multiplex cytokine measurement in ACPA-positive, MTX-naïve eRA and OA

We selected five cytokines representing Th1 cells (IFN-γ), Th17 cells (IL-17A), APCs (IL-12), or pro-inflammatory cytokines (IL-6 and TNF-α) and evaluated expression levels using MCA. All five cytokines were significantly elevated in ACPA-positive, MTX-naïve eRA (N = 28) compared with OA (N = 16; Fig. 2A). Significant correlations were observed between IFN-γ and IL-17A/IL-6/IL-12/TNF-α (Fig. 2B). DAS28-ESR were correlated with IFN-γ, IL-6, and IL-12 (Fig. 2C). Moreover, patients with a relatively low inflammatory status in eRA (high sensitivity C-reactive protein [hs-CRP] < 0.5 mg/dL; N = 20) exhibited higher levels of
CD4+ T cell-related cytokines, including IFN-γ and IL-17A, were dramatically upregulated in the peripheral blood of patients with ACPA-positive, MTX-naïve eRA.

**Plasma cytokine measurement via MCA in patients with established RA and OA controls**

We measured the plasma levels of 5 cytokines in patients with established RA (N = 58) and OA (N = 16) group. Among established RA, 34 of 58 patients achieved low disease activity (DAS28-ESR ≤ 3.2) after DMARDs treatment. Both IFN-γ and IL-17A levels were elevated in patients with established RA with low disease activity compared with those in OA group (Supplementary Fig. 1A). In contrast, 25 of 58 patients remained with moderate to high disease activity (DAS28-ESR > 3.2), all five cytokines were significantly increased, compared with the OA group (Supplementary Fig. 2A). In patients with established RA with low disease activity, plasma IFN-γ levels were correlated with plasma IL-17A, IL-6, IL-12, and TNF-α levels (Supplementary Fig. 1B). Disease activity was not significantly correlation with plasma IFN-γ, IL-6, IL12, or TNF-α (Supplementary Fig. 1C). In patients with established RA with moderate to high disease activity, plasma IFN-γ levels were correlated with IL-17A, IL-12, and TNF-α (Supplementary Fig. 2B). DAS28-ESR levels were significantly correlated with all five cytokine plasma levels (Supplementary Fig. 2C).

Notably, in comparison of OA, the mean levels of IFN-γ was significantly higher in early stage of RA as well as in established RA with low disease activity. Therefore, in addition to IL-17, plasma IFN-γ levels could be useful for diagnostic biomarker in early stage of RA, as well as responsible for chronic inflammatory status of patients with DMRDs treated established RA.

**Evaluation of clinical outcome according to plasma IFN-γ in patients with low disease activity**

After 6 months follow up, RA patients with LDA (N = 34) were able to divide into 3 group of clinical outcome. To evaluate the impact of IFN-γ on clinical outcome, the plasma levels of IFN-γ and IL-17A were measured at time of achieving low disease activity and compared with 3 different clinical outcomes after approximately 6 months. The plasma levels of IFN-γ in drug free / drug reduction group were lower than drug maintenance and relapse group (13.61 ± 5.54 vs 28.26 ± 17.69 vs 39.15 ± 18.59 pg/mL, respectively, Fig. 3A). The plasma level of IL-17A showed similar results with IFN-γ between drug free / drug reduction, drug maintenance, and relapse group (10.91 ± 3.78 vs 21.33 ± 13.49 vs 19.42 ± 2.12 pg/mL, respectively, Fig. 3B).

**Discussion**

In this study, we evaluated gene expression patterns in ACPA-positive, MTX-naïve eRA and assessed the roles of cytokines as biomarkers of clinical treatment response. ACPA-positive, MTX-naïve eRA was associated with upregulation of IFN-γ and IL-17A gene signatures. Moreover, among patients with ACPA-positive, MTX-naïve eRA or established RA with moderate to high disease activity, plasma IFN-γ levels
correlated well with other inflammatory cytokines, including IL-12 and IL-17A, and with clinical disease activity. Notably, in patients with RA with low disease activity, plasma IFN-γ and IL-17A levels may enable to discriminate the patients who can tolerate drug tapering or achieve drug-free remission.

Over 100 genes have shown to be associated with RA [28], and many RA-associated risk factor genes are dominantly expressed in CD4+ T cells [23]. Additionally, the gene enhancer region (H3K4me1) is uniformly overlapped with most effector and memory CD4+ T cells [24], highlighting the roles of CD4+ T cell in RA pathogenesis. In this study, we showed that IFN-γ- and IL-17A-associated genes were significantly increased in these patients, suggesting the potential roles of Th1 and Th17 cells in early stage RA pathogenesis. Interestingly, five upregulated genes in patients with ACPA-positive, MTX-naïve eRA were related to both IFN-γ and IL-17A signalling, and these genes may provide important insights into molecular targeting in RA.

IFN-γ plays crucial roles in primary immune defence against microbial infection and is considered a pro-inflammatory cytokine. However, IFN-γ has been shown to have both pro-inflammatory and anti-inflammatory activities under different biological contexts [29]. Importantly, RA synovium exhibits increased IFN-γ expression [30], and IFN-γ+ CD4+ T cells are dominant in RA synovial fluid [31]. In patients with RA, collagen type II reactive T cells produce more IFN-γ than IL-4, suggesting an autoreactive T-cell skew toward the Th1 phenotype [12]. However, animal models of RA have shown conflicting results; some have suggested that IFN-γ induces arthritis [15], whereas others have demonstrated that IFN-γ has protective effects against arthritis [13, 14]. Furthermore, IFN-γ reduces osteoclast formation, which is essential for joint destruction in RA [32]. After the discovery of Th17 cells, IFN-γ was found to suppress arthritis by regulating Th17 cell development [33, 34]. A recent study found that five IFN-related genes (MxA, IFI6, OAS1, ISG15, and IFI44L) were highly expressed in MTX-naïve RA compared with that in established RA, and this upregulation was correlated with disease activity and predicted treatment resistance in MTX-naïve RA [25]. In the current study, OAS1 and IFI44L were also significantly increased in ACPA-positive, MTX-naïve eRA. Furthermore, increased CXCL10 levels in MTX-naïve eRA have been found to be correlated with disease activity [35]. Similarly, we showed that plasma CXCL10 levels were significantly elevated in MTX-naïve eRA compared with that in established RA. Our findings suggested that IFN-γ-related genes could play important roles in RA pathogenesis, particularly during the early phase.

Th17 cells are the primary producers of IL-17 among all CD4+ T cells [8]. Additionally, Th17 cells are now considered the main pathological cells in RA pathogenesis [36, 37]. IL-17 induces osteoclastogenesis [38], and Th17 levels are correlated with RA disease activity [39]. Moreover, IL-17 is involved in the pathological processes of early or preclinical RA; IL-17 blocking agents show inferior therapeutic responses compared with other biologic DMARDs, including TNF-α inhibitors, in established RA [40]. Patients with RA with higher proportions of circulating Th1 and Th17 cells show poor clinical responses, indicating the potential predictive roles of Th1 and Th17 in treatment response [41]. Discontinuation or tapering of DMARD is a major goal of RA treatment; however, few predictors of this strategy have been identified [42]. In the current study, IFN-γ- and IL-17A-associated genes and CXCL10 were significantly elevated in ACPA-
positive, MTX-naïve eRA. Plasma IFN-γ and IL-17A levels were significantly elevated in ACPA positive MTX naïve eRA even in patients with a low inflammatory status. Additionally, plasma IFN-γ and IL-17A levels in established RA with low disease activity were associated with drug-free or dose reduction at 6 months. Thus, these cytokines may play crucial roles in early RA pathogenesis and may be useful for prediction of tapering or discontinuing RA medication.

Dual overexpression of IFN-γ- and IL-17A-related gene signatures is an interesting phenomenon. Th1 and Th17 signals typically suppress each other [43, 44]; however, in this study, both IFN-γ- and IL-17A-related genes were upregulated in ACPA-positive, MTX-naïve eRA. This result could be explained by several hypotheses. First, Th1 and Th17 signals could both be upregulated and both suppress the other, and this could be described as "sleeping with enemy". In vitro, autoreactive PTM peptide promotes Th17 induction in RA [45, 46]. Moreover, autoreactive T-cell responses to type II collagen show skewing toward Th1 [12]. In animal models, collagen injection induces Th1 polarisation [47], and STAT3 inhibition ameliorates arthritis severity by reducing the Th17 population in a collagen-induced arthritis (CIA) model [48]. In addition, type II collagen-stimulated CD4+ T cells from patients with RA exhibit increased IFN-γ and IL-17 production [49]. Theoretically, PTM autoreactive peptide can induce both Th1 and Th17 dominant responses. IFN-γ suppresses Th17 differentiation in CIA and experimental autoimmune encephalitis by inducing IDO in APCs or via suppressor of cytokine signalling (SOCS) [33, 50]. SOCS has several subtypes and acts as an intracellular regulator for the Janus kinase (JAK)/STAT pathway. SOCS1 is critical a negative regulator of IFN-γ/STAT1 signalling and suppresses Th1 differentiation [51]. Furthermore, SOCS1 simultaneously enhances Th17 differentiation via STAT3 signalling, and SOCS3 modulates Th1/Th17 responses with SOCS1 [51]. Interestingly, IFN-γ also accelerates Foxp3+ regulatory T cell (Treg) induction and enhances the regulatory functions of Tregs [52]. The protective roles of Tregs on systemic autoimmunity have been extensively studied, and Tregs have been shown to reduce Th17-mediated autoimmune responses [53]. In contrast, IL-17 downregulates Th1 induction via IL-12Rβ2 suppression [54], and the Th17-inducing transcription factor STAT3 blocks IL-12/p35 gene expression, thereby suppressing the Th1 response [55]. Citrullinated peptide reacts with the HLA-DRβ shared epitope and stimulates CD4+ T-cell responses; therefore, these PTM peptide-mediated CD4+ T-cell responses may be only observed in ACPA-positive RA. We hypothesise that initially enhanced Th1 and Th17 responses induced by the PTM peptide could counteract each other, particularly during the early stages of ACPA-positive RA pathogenesis. Second, recent studies have shown that some Th17 cells can produce IFN-γ [56]. These IFN-γ-positive Th17 cells are increased in the synovial fluid of patients with juvenile inflammatory arthritis [57], suggesting the pathological roles of this Th17 subset in inflammatory arthritis. Our study demonstrated the importance of IFN-γ and IL-17A in ACPA-positive eRA and highlighted the roles of these cytokines in drug-free remission. However, further studies are needed to determine the specific mechanisms of ACPA-positive eRA pathogenesis.

MCAs have several advantages compared with conventional ELISA. Because the minimal detectable range of MCA is lower than that of ELISA, MCA can be used to identify relatively low levels of cytokines in blood, and detect multiple cytokines at the same time using the same sample. MCA using antibody
capture with magnetic beads and razor detection can be used to measure multiple cytokines simultaneously and can detect these cytokines at levels close to the physiological concentration [58]. In our study, combinations of 5 cytokines (IFN-γ, IL-6, IL-17, TNF-α, IL-12) can detect the stable reference ranges of the same analytes and enable to determine the precise concentrations of these cytokines in patients with ACPA-positive, MTX-naïve eRA.

There were several limitations to the current study. First, the microarray data for ACPA-positive, MTX-naïve eRA were obtained from a relatively small sample size. However, our results were consistent with a previous study of MTX-naïve eRA [25]. Second, the follow-up duration for patients with established RA with low disease activity was only 6 months. Third, all patients were seropositive RA; therefore, the results from the current study cannot be generalised to seronegative RA.

**Conclusions**

In conclusion, our findings showed that increased IFN-related gene signalling in CD4+ T cells was critical in ACPA-positive eRA. Simultaneous increases in the concentrations of IFN-γ and IL-17 in the blood could affects disease onset and cause associated with clinical disease activity after achieving low disease activity in established RA. Patients with low circulating levels of IFN-γ and IL-17A tended to show a fair clinical response, allowing reduction of the dosage of DMARDs over 6 months in established RA. In particular, the continued decrease in blood levels of IFN-γ suggested the possibility of achieving complete remission in the future (the concept of complete cytokine remission). Our current analysis of gene expression and plasma IFN-γ levels provides important insights into the discovery of new biomarkers of disease onset and the chronic pathological process in patients with RA. The potential roles of IFN-γ in RA were confirmed by our results, and these findings could have implications in translation research from bench to bedside.

**Abbreviations**

RA: rheumatoid arthritis; FLS: fibroblast-like synoviocyte; eRA: early rheumatoid arthritis; PTM: post-translational modification; ACPA: anti-citrullinated protein antibody; APC: antigen-presenting cell; CD: cluster of differentiation; Th17: type 17 helper T cell; IFN: interferon; HLA: human leukocyte antigen; SNP: single nucleotide polymorphism; STAT: signal transducer and activator of transcription; eQTL: expression quantitative trait loci; MTX: methotrexate; ACR: American college of rheumatology; DMARD: disease-modifying antirheumatic drug; DAS: disease activity score; ESR: erythrocyte sedimentation rate; OA: osteoarthritis; CXCL: C-X-C motif chemokine ligand; ELISA: Enzyme-linked immunosorbent assay; MCA: multiplex cytokine assay; IL: interleukin; TNF: tumor necrosis factor; RT-qPCR: reverse transcription quantitative polymerase chain reaction; PBMC: peripheral blood mononuclear cell; PBS: phosphate-buffered saline; hs-CRP: high sensitivity C-reactive protein; CIA: collagen-induced arthritis; SOCS: suppressor of cytokine signaling; JAK: janus kinase; Treg: regulatory T cell

**Declarations**
Ethics approval and consent to participate

Informed consent was obtained from all patients, and the study was approved by the Human Research Ethics Committee of the Konkuk University Medical Center (approval no. KUH1010511) and the Clinics for Arthritis and Rheumatism (approval no. 0301202005BR00101).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This research was supported by a grant of the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology, Republic of Korea (NRF-2013R1A1A2059368).

Authors' contributions

HYK and JHJ designed the study and achieved clinical data. HYK developed the theory. KL performed the experiments, statistical analysis, and formed the figures. SHK performed the multiplex cytokine measuring experiment. HRK and SHL interpreted the data and recruited the clinical information of the enrolled patients. HKM wrote the manuscript and did the statistical analysis. All authors read and approved the final manuscript.

Acknowledgements

Not applicable

References

1. Aletaha D, Smolen JS: Diagnosis and Management of Rheumatoid Arthritis: A Review. Jama 2018, 320:1360-1372.
2. Kraan MC, Reece RJ, Smeets TJ, Veale DJ, Emery P, Tak PP: Comparison of synovial tissues from the knee joints and the small joints of rheumatoid arthritis patients: Implications for pathogenesis and evaluation of treatment. Arthritis Rheum 2002, 46:2034-2038.
3. Kim HY, Kim WU, Cho ML, Lee SK, Youn J, Kim SI, Yoo WH, Park JH, Min JK, Lee SH, et al: Enhanced T cell proliferative response to type II collagen and synthetic peptide CII (255-274) in patients with rheumatoid arthritis. Arthritis Rheum 1999, 42:2085-2093.

4. Trouw LA, Rispens T, Toes REM: Beyond citrullination: other post-translational protein modifications in rheumatoid arthritis. Nat Rev Rheumatol 2017, 13:331-339.

5. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K: Rheumatoid arthritis. Nat Rev Dis Primers 2018, 4:18001.

6. Kondo Y, Yokosawa M, Kaneko S, Furuyama K, Segawa S, Tsuboi H, Matsumoto I, Sumida T: Review: Transcriptional Regulation of CD4+ T Cell Differentiation in Experimentally Induced Arthritis and Rheumatoid Arthritis. Arthritis Rheumatol 2018, 70:653-661.

7. Morita Y, Yamamura M, Kawashima M, Harada S, Tsuji K, Shibuya K, Maruyama K, Makino H: Flow cytometric single-cell analysis of cytokine production by CD4+ T cells in synovial tissue and peripheral blood from patients with rheumatoid arthritis. Arthritis Rheum 1998, 41:1669-1676.

8. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT: Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.

9. Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C: A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.

10. Schulze-Koops H, Kalden JR: The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001, 15:677-691.

11. James EA, Rieck M, Pieper J, Gebe JA, Yue BB, Tatum M, Peda M, Sandin C, Klareskog L, Malmstrom V, Buckner JH: Citrulline-specific Th1 cells are increased in rheumatoid arthritis and their frequency is influenced by disease duration and therapy. Arthritis Rheumatol 2014, 66:1712-1722.

12. Park SH, Min DJ, Cho ML, Kim WU, Youn J, Park W, Cho CS, Kim HY: Shift toward T helper 1 cytokines by type II collagen-reactive T cells in patients with rheumatoid arthritis. Arthritis Rheum 2001, 44:561-569.

13. Matthys P, Vermeire K, Mitera T, Heremans H, Huang S, Schols D, De Wolf-Peeters C, Billiau A: Enhanced autoimmune arthritis in IFN-gamma receptor-deficient mice is conditioned by mycobacteria in Freund's adjuvant and by increased expansion of Mac-1+ myeloid cells. J Immunol 1999, 163:3503-3510.

14. Vermeire K, Heremans H, Vandeputte M, Huang S, Billiau A, Matthys P: Accelerated collagen-induced arthritis in IFN-gamma receptor-deficient mice. J Immunol 1997, 158:5507-5513.

15. Frey O, Mitera T, Kelchtermans H, Schurgers E, Kamradt T, Matthys P: Ameliorated course of glucose-6-phosphate isomerase (G6PI)-induced arthritis in IFN-gamma receptor knockout mice exposes an arthritis-promoting role of IFN-gamma. J Autoimmun 2011, 36:161-169.

16. Machold KP, Neumann K, Smolen JS: Recombinant human interferon gamma in the treatment of rheumatoid arthritis: double blind placebo controlled study. Ann Rheum Dis 1992, 51:1039-1043.
17. Sigidin YA, Loukina GV, Skurkovich B, Skurkovich S: Randomized, double-blind trial of anti-interferon-gamma antibodies in rheumatoid arthritis. *Scand J Rheumatol* 2001, **30**:203-207.

18. Viatte S, Plant D, Raychaudhuri S: Genetics and epigenetics of rheumatoid arthritis. *Nat Rev Rheumatol* 2013, **9**:141-153.

19. Gregersen PK, Silver J, Winchester RJ: The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. *Arthritis Rheum* 1987, **30**:1205-1213.

20. Raychaudhuri S, Sandor C, Stahl EA, Freudenberg J, Lee HS, Jia X, Alfredsson L, Padyukov L, Klareskog L, Worthington J, et al: Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. *Nat Genet* 2012, **44**:291-296.

21. Okada Y, Eyre S, Suzuki A, Kochi Y, Yamamoto K: Genetics of rheumatoid arthritis: 2018 status. *Ann Rheum Dis* 2019, **78**:446-453.

22. Pratt AG, Swan DC, Richardson S, Wilson G, Hilkens CM, Young DA, Isaacs JD: A CD4 T cell gene signature for early rheumatoid arthritis implicates interleukin 6-mediated STAT3 signalling, particularly in anti-citrullinated peptide antibody-negative disease. *Ann Rheum Dis* 2012, **71**:1374-1381.

23. Raj T, Rothamel K, Mostafavi S, Ye C, Lee MN, Replogle JM, Feng T, Lee M, Asinovski N, Frohlich I, et al: Polarization of the effects of autoimmune and neurodegenerative risk alleles in leukocytes. *Science* 2014, **344**:519-523.

24. Walsh AM, Whitaker JW, Huang CC, Cherkas Y, Lamberth SL, Brodmerkel C, Curran ME, Dobrin R: Integrative genomic deconvolution of rheumatoid arthritis GWAS loci into gene and cell type associations. *Genome Biol* 2016, **17**:79.

25. Cooles FAH, Anderson AE, Lendrem DW, Norris J, Pratt AG, Hilkens CMU, Isaacs JD: The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy. *J Allergy Clin Immunol* 2018, **141**:445-448.e444.

26. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al.: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum* 1988, **31**:315-324.

27. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, et al: 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010, **62**:2569-2581.

28. Okada Y, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Kawaguchi T, Stahl EA, Kurreeman FA, Nishida N, et al: Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. *Nat Genet* 2012, **44**:511-516.

29. Lees JR: Interferon gamma in autoimmunity: A complicated player on a complex stage. *Cytokine* 2015, **74**:18-26.

30. Dolhain RJ, ter Haar NT, Hoefakker S, Tak PP, de Ley M, Claassen E, Breedveld FC, Miltenburg AM: Increased expression of interferon (IFN)-gamma together with IFN-gamma receptor in the rheumatoid
synovial membrane compared with synovium of patients with osteoarthritis. *Br J Rheumatol* 1996, **35**:24-32.

31. Yin Z, Siegert S, Neure L, Grolms M, Liu L, Eggens U, Radbruch A, Braun J, Sieper J: The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta. *Rheumatology (Oxford)* 1999, **38**:1058-1067.

32. Takahashi N, Mundy GR, Roodman GD: Recombinant human interferon-gamma inhibits formation of human osteoclast-like cells. *J Immunol* 1986, **137**:3544-3549.

33. Lee J, Lee J, Park MK, Lim MA, Park EM, Kim EK, Yang EJ, Lee SY, Jhun JY, Park SH, et al: Interferon gamma suppresses collagen-induced arthritis by regulation of Th17 through the induction of indoleamine-2,3-deoxygenase. *PLoS One* 2013, **8**:e60900.

34. Chu CQ, Swart D, Alcorn D, Tocker J, Elkon KB: Interferon-gamma regulates susceptibility to collagen-induced arthritis by suppression of interleukin-17. *Arthritis Rheum* 2007, **56**:1145-1151.

35. Pandya JM, Lundell AC, Andersson K, Nordstrom I, Theander E, Rudin A: Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker. *Arthritis Res Ther* 2017, **19**:20.

36. Yamada H, Nakashima Y, Okazaki K, Mawatari T, Fukushima JI, Kaibara N, Horii A, Iwamoto Y, Yoshikai Y: Th1 but not Th17 cells predominate in the joints of patients with rheumatoid arthritis. *Ann Rheum Dis* 2008, **67**:1299-1304.

37. van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, Dolhain RJ, Lubberts E: Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. *Arthritis Rheum* 2011, **63**:73-83.

38. Kim KW, Kim HR, Kim BM, Cho ML, Lee SH: Th17 cytokines regulate osteoclastogenesis in rheumatoid arthritis. *Am J Pathol* 2015, **185**:3011-3024.

39. Miao J, Geng J, Zhang K, Li X, Li Q, Li C, Zhu P: Frequencies of circulating IL-17-producing CD4+CD161+ T cells and CD4+CD161+ T cells correlate with disease activity in rheumatoid arthritis. *Mod Rheumatol* 2014, **24**:265-570.

40. Tlustochowicz W, Rahman P, Seriolo B, Krammer G, Porter B, Widmer A, Richards HB: Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study. *J Rheumatol* 2016, **43**:495-503.

41. Alvandpur N, Tabatabaei R, Tahamoli-Roudsari A, Basiri Z, Behzad M, Rezaeepoor M, Roshanaei G, Hajilooi M, Solgi G: Circulating IFN-gamma producing CD4+ T cells and IL-17A producing CD4+ T cells, HLA-shared epitope and ACPA may characterize the clinical response to therapy in rheumatoid arthritis patients. *Hum Immunol* 2020.

42. Tweehuysen L, van den Ende CH, Beeren FM, Been EM, van den Hoogen FH, den Broeder AA: Little Evidence for Usefulness of Biomarkers for Predicting Successful Dose Reduction or Discontinuation...
of a Biologic Agent in Rheumatoid Arthritis: A Systematic Review. Arthritis Rheumatol 2017, 69:301-308.

43. Damsker JM, Hansen AM, Caspi RR: Th1 and Th17 cells: adversaries and collaborators. Ann N Y Acad Sci 2010, 1183:211-221.

44. Leung S, Liu X, Fang L, Chen X, Guo T, Zhang J: The cytokine milieu in the interplay of pathogenic Th1/Th17 cells and regulatory T cells in autoimmune disease. Cell Mol Immunol 2010, 7:182-189.

45. von Delwig A, Locke J, Robinson JH, Ng WF: Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010, 62:143-149.

46. Tibbitt C, Falconer J, Stoop J, van Eden W, Robinson JH, Hilkens CM: Reduced TCR-dependent activation through citrullination of a T-cell epitope enhances Th17 development by disruption of the STAT3/5 balance. Eur J Immunol 2016, 46:1633-1643.

47. Mauri C, Williams RO, Walmsley M, Feldmann M: Relationship between Th1/Th2 cytokine patterns and the arthritogenic response in collagen-induced arthritis. Eur J Immunol 1996, 26:1511-1518.

48. Son HJ, Lee J, Lee SY, Kim EK, Park MJ, Kim KW, Park SH, Cho ML: Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17/Treg balance and osteoclastogenesis. Mediators Inflamm 2014, 2014:973986.

49. Cho ML, Yoon CH, Hwang SY, Park MK, Min SY, Lee SH, Park SH, Kim HY: Effector function of type II collagen-stimulated T cells from rheumatoid arthritis patients: cross-talk between T cells and synovial fibroblasts. Arthritis Rheum 2004, 50:776-784.

50. Tanaka K, Ichiyama K, Hashimoto M, Yoshida H, Takimoto T, Takaesu G, Torisu T, Hanada T, Yasukawa H, Fukuyama S, et al: Loss of suppressor of cytokine signaling 1 in helper T cells leads to defective Th17 differentiation by enhancing antagonistic effects of IFN-gamma on STAT3 and Smads. J Immunol 2008, 180:3746-3756.

51. Tamiya T, Kashiwagi I, Takahashi R, Yasukawa H, Yoshimura A: Suppressors of cytokine signaling (SOCS) proteins and JAK/STAT pathways: regulation of T-cell inflammation by SOCS1 and SOCS3. Arterioscler Thromb Vasc Biol 2011, 31:980-985.

52. Wang Z, Hong J, Sun W, Xu G, Li N, Chen X, Liu A, Xu L, Sun B, Zhang JZ: Role of IFN-gamma in induction of Foxp3 and conversion of CD4+ CD25- T cells to CD4+ Tregs. J Clin Invest 2006, 116:2434-2441.

53. Noack M, Miossec P: Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.

54. Toh ML, Kawashima M, Zrioual S, Hot A, Miossec P, Miossec P: IL-17 inhibits human Th1 differentiation through IL-12R beta 2 downregulation. Cytokine 2009, 48:226-230.

55. Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H: Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 2009, 15:114-123.

56. Boniface K, Blumenschein WM, Brovont-Porth K, McGeachy MJ, Basham B, Desai B, Pierce R, McClanahan TK, Sadekova S, de Waal Malefyt R: Human Th17 cells comprise heterogeneous
subsets including IFN-gamma-producing cells with distinct properties from the Th1 lineage. *J Immunol* 2010, 185:679-687.

57. Nistala K, Adams S, Cambbrook H, Ursu S, Olivito B, de Jager W, Evans JG, Cimaz R, Bajaj-Elliott M, Wedderburn LR: **Th17 plasticity in human autoimmune arthritis is driven by the inflammatory environment.** *Proc Natl Acad Sci U S A* 2010, 107:14751-14756.

58. Baker HN, Murphy R, Lopez E, Garcia C: **Conversion of a capture ELISA to a Luminex xMAP assay using a multiplex antibody screening method.** *J Vis Exp* 2012.

**Tables**
Table 1.  
Selected over-expressed 34 genes in ACPA-positive, MTX-naive eRA by 6-fold change

| Gene Accession | Gene Symbol | ACPA-positive, MTX-naive eRA/OA. Fold change | P value | Gene Description |
|----------------|-------------|-----------------------------------------------|---------|------------------|
| NM_001565      | CXCL10      | 166.062                                       | 0.022   | chemokine (C-X-C motif) ligand 10 |
| NM_001031683   | IFIT3       | 64.937                                        | 0.005   | interferon-induced protein with tetratricopeptide repeats 3 |
| NM_001547      | IFIT2       | 36.972                                        | 0.006   | interferon-induced protein with tetratricopeptide repeats 2 |
| NM_001291469   | CCL4L2      | 26.572                                        | 0.001   | chemokine (C-C motif) ligand 4-like |
| NM_002984      | CCL4        | 24.244                                        | 0.002   | chemokine (C-C motif) ligand 4 |
| AK092813       | IFIT1       | 23.994                                        | 0.009   | interferon-induced protein with tetratricopeptide repeats 1 |
| NM_000575      | IL1A        | 23.857                                        | 0.003   | interleukin 1, alpha |
| NM_080657      | RSAD2       | 18.130                                        | 0.014   | radical S-adenosyl methionine domain containing 2 |
| AB208912       | GBP1        | 14.195                                        | 0.008   | guanylate binding protein 1, interferon-inducible |
| NM_001001437   | CCL3L3      | 13.427                                        | 0.001   | chemokine (C-C motif) ligand 3-like 3 |
| NM_000600      | IL6         | 12.948                                        | 0.027   | interleukin 6 |
| ENST00000325042| LOC541472   | 11.680                                        | 0.019   | uncharacterized LOC541472 |
| NM_007115      | TNFAIP6     | 11.397                                        | 0.019   | tumor necrosis factor, alpha-induced protein 6 |
| NM_001130046   | CCL20       | 11.061                                        | 0.003   | chemokine (C-C motif) ligand 20 |
| NM_006417      | IFI44       | 10.553                                        | 0.005   | interferon-induced protein 44 |
| NM_001282588   | SLAMF7      | 9.976                                         | 0.034   | SLAM family member 7 |
| NM_020980      | AQP9        | 9.652                                         | 0.007   | aquaporin 9 |
| NM_022168      | IFI44L      | 9.363                                         | 0.003   | interferon induced with helicase C domain 1 |
| NM_000963      | PTGS2       | 8.455                                         | 0.010   | prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) |
| NM_006820      | IFI44L      | 8.321                                         | 0.032   | interferon-induced protein 44-like |
| Accession     | Gene Symbol | Gene Name                                      | Log2 Fold | P-Value | Description                                                                 |
|--------------|-------------|-----------------------------------------------|-----------|---------|-----------------------------------------------------------------------------|
| NM_001261825 | OASL        | 2-5-oligoadenylate synthetase-like            | 8.057     | 0.004   |                                                                             |
| NM_016323    | HERC5       | HECT and RLD domain containing E3 ubiquitin protein ligase 5 | 7.906     | 0.006   |                                                                             |
| NM_018370    | DRAM1       | DNA-damage regulated autophagy modulator 1     | 7.287     | 0.019   |                                                                             |
| NM_014314    | DDX58       | DEAD (Asp-Glu-Ala-Asp) box polypeptide 58      | 7.063     | 0.006   |                                                                             |
| AB044545     | OAS3        | 2-5-oligoadenylate synthetase 3, 100kDa       | 7.027     | 0.012   |                                                                             |
| NM_002852    | PTX3        | pentraxin 3, long                             | 7.022     | 0.023   |                                                                             |
| NM_001143818 | SERPINB2    | serpin peptidase inhibitor, clade B (ovalbumin), member 2 | 6.843     | 0.012   |                                                                             |
| NM_152703    | SAMD9L      | sterile alpha motif domain containing 9-like   | 6.520     | 0.014   |                                                                             |
| NM_207315    | CMPK2       | cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial | 6.423     | 0.007   |                                                                             |
| NM_001032409 | OAS1        | 2-5-oligoadenylate synthetase 1, 40/46kDa     | 6.315     | 0.007   |                                                                             |
| NM_014398    | LAMP3       | lysosomal-associated membrane protein 3        | 6.240     | 0.049   |                                                                             |
| NR_001458    | MIR155HG    | MIR155 host gene (non-protein coding)          | 6.213     | 0.013   |                                                                             |
| NR_037867    | LOC731424   | uncharacterized LOC731424                     | 6.143     | 0.045   |                                                                             |
| NM_012420    | IFIT5       | interferon-induced protein with tetratricopeptide repeats 5 | 6.083     | 0.002   |                                                                             |
| Gene Accession | Gene symbol | ACPA-positive, MTX-naïve eRA/OA. Fold change | P value | Gene Description |
|---------------|------------|----------------------------------|---------|-----------------|
| NM_001565     | CXCL10     | 166.062                          | 0.022   | chemokine (C-X-C motif) ligand 10 |
| NM_001031683  | IFIT3      | 64.937                           | 0.005   | interferon-induced protein with tetratricopeptide repeats 3 |
| NM_001547     | IFIT2      | 36.972                           | 0.006   | interferon-induced protein with tetratricopeptide repeats 2 |
| NM_001291469  | CCL4L2     | 26.572                           | 0.001   | chemokine (C-C motif) ligand 4-like 2 |
| NM_002984     | CCL4       | 24.244                           | 0.002   | chemokine (C-C motif) ligand 4 |
| AK092813      | IFIT1      | 23.994                           | 0.009   | interferon-induced protein with tetratricopeptide repeats 1 |
| NM_080657     | RSAD2      | 18.130                           | 0.014   | radical S-adenosyl methionine domain containing 2 |
| AB208912      | GBP1       | 14.195                           | 0.008   | guanylate binding protein 1, interferon-inducible |
| NM_007115     | TNFAIP6    | 11.397                           | 0.019   | tumor necrosis factor, alpha-induced protein 6 |
| NM_001130046  | CCL20      | 11.061                           | 0.003   | chemokine (C-C motif) ligand 20 |
| NM_006417     | IFI44      | 10.553                           | 0.005   | interferon-induced protein 44 |
| NM_001282588  | SLAMF7     | 9.976                            | 0.034   | SLAM family member 7 |
| NM_022168     | IFIH1      | 9.363                            | 0.003   | interferon induced with helicase C domain 1 |
| NM_006820     | IFI44L     | 8.321                            | 0.032   | interferon-induced protein 44-like |
| NM_001261825  | OASL       | 8.057                            | 0.004   | 2-5-oligoadenylate synthetase-like |
| NM_016323     | HERC5      | 7.906                            | 0.006   | HECT and RLD domain containing E3 ubiquitin protein ligase 5 |
| AB044545      | OAS3       | 7.027                            | 0.012   | 2-5-oligoadenylate synthetase 3, 100kDa |
| NM_001032409  | OAS1       | 6.315                            | 0.007   | 2-5-oligoadenylate synthetase 1, 40/46kDa |
| NM_012420     | IFIT5      | 6.083                            | 0.002   | interferon-induced protein with tetratricopeptide repeats 5 |
Table 3.
List of the 8 IL-17A related genes of 6-fold ACPA-positive, MTX-naïve eRA specific genes

| Gene Accession | Gene symbol | ACPA-positive, MTX-naïve eRA/OA. Fold change | P value | Gene Description |
|----------------|-------------|----------------------------------------------|---------|-----------------|
| NM_001031683   | IFIT3       | 64.937                                       | 0.005   | interferon-induced protein with tetratricopeptide repeats 3 |
| NM_080657      | RSAD2       | 18.130                                       | 0.014   | radical S-adenosyl methionine domain containing 2 |
| AB208912       | GBP1        | 14.195                                       | 0.008   | guanylate binding protein 1, interferon-inducible |
| NM_001130046   | CCL20       | 11.061                                       | 0.003   | chemokine (C-C motif) ligand 20 |
| NM_001261825   | OASL        | 8.057                                        | 0.004   | 2-5-oligoadenylate synthetase-like |
| NM_152703      | SAMD9L      | 6.520                                        | 0.014   | sterile alpha motif domain containing 9-like |
| NM_207315      | CMPK2       | 6.423                                        | 0.007   | cytidine monophosphate (UMP-CMP) kinase 2, mitochondrial |
| NM_014398      | LAMP3       | 6.240                                        | 0.049   | lysosomal-associated membrane protein 3 |

Figures
Figure 1

Microarray analysis and RT-qPCR of ACPA-positive, MTX-naïve early RA (eRA). (A) Total microarray analysis data of CD4+ T cells from patients with ACPA-positive, MTX-naïve eRA or OA. (B) Three-fold and six-fold upregulated genes in ACPA-positive, MTX-naïve eRA. (C) Validation of 10 upregulated genes in ACPA-positive, MTX-naïve eRA by RT-qPCR. (D) Plasma levels of CXCL-10 in ACPA-positive, MTX-naïve eRA, established RA, and OA.
Figure 2

Multiplex cytokine assay of ACPA-positive, MTX-naïve eRA. (A) Plasma cytokine levels of five cytokines (IFN-γ, IL-17A, IL-6, IL-12, TNF-α) in patients with ACPA-positive, MTX-naïve eRA. (B) Correlation between plasma IFN-γ and IL-17A/IL-6/IL-12/TNF-α. (C) Correlation between DAS28-ESR and plasma cytokine levels. (D) Plasma cytokine levels in patients with ACPA-positive, MTX-naïve eRA with hs-CRP under 0.5 mg/dL.
Figure 3

IFN-γ and IL-17A levels in established RA with low disease activity (DAS28-ESR ≤ 3.2). (A) Comparison of baseline plasma levels of IFN-γ in the established RA with drug-free or drug reduction, drug maintenance, and relapse after dose reduction groups. (B) Comparison of baseline plasma levels of IL-17A in the established RA with drug-free or drug reduction, drug maintenance, and relapse after dose reduction groups.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarymaterials.docx